

Tifcemalimab Biosimilar - Research Grade

Product Code: ICH5920

More Information

Species Reactivity: Human

Target: BTLA α 1/2

Concentration: 5mg/ml

Isotype: IgG4 - kappa

Host: CHO Cells

product name H2: Tifcemalimab Biosimilar - Research Grade

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: Q7Z6A9

Shipping Conditions: Blue ice

background: BTLA is an inhibitory immune checkpoint receptor that modulates T- and B-cell responses, drawing interest in cancer immunology and autoimmunity research. The reagent here is a research-grade, unconjugated analog of tifcemalimab, a recombinant anti-BTLA monoclonal antibody for research use only. It is produced to in vivo standards with low endotoxin and supplied in scalable milligram to gram quantities for bulk and high-throughput laboratories. The antibody supports checkpoint-modulation functional assays, in vitro lymphocyte-activation screens, and in vivo immune-modulation models. Reliable batch-to-batch consistency helps standardize comparisons across in vitro and in vivo experiments. Its purity and dependable supply support reproducible work in demanding, high-throughput settings.



Other names: BTLA1, CD272, B and T lymphocyte associated

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >90% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 3-4 weeks